Chavez Miguel A, Heidari Behnam, Thacker Sameer, Samuel Leena L, Ogbonna Martina
Internal Medicine, Houston Methodist Hospital, Houston, USA.
Cureus. 2020 Jun 7;12(6):e8495. doi: 10.7759/cureus.8495.
Acute myelogenous leukemia (AML) is one of the most common hematologic malignancies. Among them, acute promyelocytic leukemia (APL) is well known for its coagulopathies. Bleeding secondary to disseminated intravascular coagulation, is a common initial presentation and carries a high risk for mortality if left untreated. Thrombotic complications are uncommon and can be related to treatment with chemotherapeutic agents. Large artery thrombosis is very rare, and standardized management remains elusive given the classic revascularization techniques carry a significant risk of re-thrombosis, as well as high risk for mortality given the multiple surgical and percutaneous interventions that are attempted. A multidisciplinary approach is necessary in these cases to carefully weigh the risk and benefits as the classical approach to revascularization and acute arterial thrombosis could potentially cause harm.
急性髓系白血病(AML)是最常见的血液系统恶性肿瘤之一。其中,急性早幼粒细胞白血病(APL)以其凝血功能障碍而闻名。弥散性血管内凝血继发的出血是常见的初始表现,若不治疗,死亡率很高。血栓形成并发症并不常见,可能与化疗药物治疗有关。大动脉血栓形成非常罕见,鉴于经典的血管再通技术存在再次血栓形成的重大风险,以及由于尝试的多种外科和经皮干预措施导致的高死亡风险,标准化管理仍然难以实现。在这些情况下,多学科方法是必要的,以便仔细权衡风险和益处,因为经典的血管再通和急性动脉血栓形成方法可能会造成伤害。